Drug data last refreshed 37m ago · AI intelligence enriched 2w ago
Octaplas is a human plasma protein solution administered intravenously, derived from pooled donor plasma. It is used for plasma replacement in patients requiring coagulation factor supplementation or volume restoration. The product provides a balanced physiologic composition of clotting factors and other essential plasma proteins.
Product is at peak commercial maturity with moderate competitive pressure (30), indicating stable team size and established go-to-market execution.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Observational Study of the Use of octaplasLG®.
Octaplas Adult TTP Trial
Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation
Octaplas Pediatric Plasma Exchange Trial
Octaplas Pediatric Plasma Replacement Trial
Worked on Octaplas at Octapharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Octaplas offers exposure to specialty pharmaceutical commercialization in a mature, high-stakes clinical market (trauma, surgery, ICU). Team roles emphasize relationship management with hospitals and transfusion services, clinical credibility, and supply chain reliability rather than innovation.